Compass Therapeutics (CMPX) Cash from Investing Activities (2019 - 2026)

Compass Therapeutics has disclosed Cash from Investing Activities across 8 years of filings, most recently posting $38.4 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $38.4 million, up 231.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$66.5 million (down 206.41% YoY), and the FY2025 annual result was -$93.3 million, down 299.49% from the prior year.
• Cash from Investing Activities came in at $38.4 million for Q1 2026 at Compass Therapeutics, up from -$3.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $38.4 million in Q1 2026 to a low of -$105.5 million in Q2 2022.
• The 5-year median for Cash from Investing Activities is $1.2 million (2022), against an average of -$7.8 million.
• Across the five-year window, Cash from Investing Activities slumped 17089.09% in 2022 and jumped 2311.92% in 2023, its largest moves.
• Compass Therapeutics' Cash from Investing Activities stood at -$46.6 million in 2022, then soared by 113.54% to $6.3 million in 2023, then surged by 143.43% to $15.4 million in 2024, then slumped by 121.98% to -$3.4 million in 2025, then surged by 1237.63% to $38.4 million in 2026.
• The last three Cash from Investing Activities figures came in at $38.4 million (Q1 2026), -$3.4 million (Q4 2025), and -$95.2 million (Q3 2025), per Business Quant data.